Seeking Alpha
 

Optimer Pharmaceuticals, Inc. (OPTR)

- NASDAQ
OPTR is defunct.
  • Apr. 9, 2012, 7:55 AM
    Shares of Optimer Pharmaceuticals (OPTR) come off their trading halt down 4.7% premarket after the firm cleans house and warns that Q1 revenue will be lower than the estimates of analysts.
    | Comment!
  • Apr. 9, 2012, 7:35 AM
    It's complete upheaval at Optimer Pharmaceuticals (OPTR), where the Chairman, CFO, and a VP have all been removed due to lapses in corporate governance practices. Shares halted premarket.
    | Comment!
  • Apr. 2, 2012, 6:54 AM
    Optimer Pharmaceuticals (OPTR) announces positive results from a pair of Phase 3 trials on the benefits of its fidaxomicin tablets compared to oral vancomycin for cancer patients.
    | Comment!
  • Mar. 7, 2012, 6:01 PM
    More on Optimer Pharmaceuticals (OPTR): Q4 beats revenue expectations as the early launch of its new drug Dificid adds $11M in sales to its top line. Shares +0.9% AH.
    | Comment!
  • Mar. 7, 2012, 5:25 PM
    Optimer Pharmaceuticals (OPTR): Q4 EPS of $0.29 may not be comparable to consensus of $0.51. Revenue of $64.6M beats by $21M. Shares +0.9% AH. (PR)
    | Comment!
  • Nov. 3, 2011, 5:16 PM
    Optimer Pharmaceuticals (OPTR) trades lower in the post-session after reporting a wider than expected Q3 loss. SG&A expenses jumped fourfold Y/Y to $26.9M, compared to $4.8M for the prior year, primarily due to its infrastructure build-up and marketing expenses related to the launch of its blockbuster drug DIFICID. Shares -7.8% AH.
    | Comment!
  • Sep. 21, 2011, 12:23 PM
    Optimer Pharmaceuticals (OPTR +3.8%) trades up after BMC initiates the shares with a buy. The firm says the company's newly launched antibiotic, Dificid, will exceed sales expectations in both the near and longer term.
    | Comment!
  • Sep. 19, 2011, 2:34 PM
    Optimer Pharmaceuticals (OPTR) is up 6.4% after Jefferies reiterates a Buy and $17 PT. The firm is bullish on better-than-expected sales of Optimer's Dificid drug, and on the pending EU launch of the drug by partner Astellas (ALPMY.PK). Jefferies also thinks milestone payment from Astellas will strengthen Optimer's cash position.
    | Comment!
  • May. 31, 2011, 9:00 AM
    Premarket gainers: YONG +50%. FCEL +14%. NBG +10%. LDK +6%. OPTR +6%. AEZS +7%. SPIL +5%. RDN +5%. BPAX +4%. NDCO +4%. LOGI +4%. PAL +4%. FSLR +4%. ASH +4%.
    Losers: NOK -11%. IRE -6%. ARNA -4%.
    | Comment!
  • May. 27, 2011, 4:20 PM
    Buy the rumor, sell the news: after a 3 week rally, Optimer Pharmaceutical (OPTR -7.2%) sells off hard after winning FDA approval for its antibiotic drug Dificid for treatment of Clostridium Difficel-Associated infections.
    | 1 Comment
  • Apr. 6, 2011, 9:00 AM
    Premarket gainers: IRE +5%. AIB +4%. KGY +4%. AG +3%. PSTI +3%. NBG +3%. BRCM +3%. HBC +3%. OCLR +3%. EXK +3%.
    Losers: AMSC -46%. VHC -3%. ALZM -3%. OPTR -3%.
    | 1 Comment
  • Apr. 1, 2011, 9:02 AM
    Premarket gainers: AIB +20%. NYX +11%. SRX +10%. OPTR +8%. GLNG +6%. CIGX +6%. HERO +4%. BCS +3%. LVS +3%. MCZ +3%. LYG +3%. MPEL +3%. SD +3%.
    Losers: LOGI -18%. AVII -18%. ODP -14%. KKD -11%. XRTX -8%. FUR -7%. AVNR -3%. PEB -3%. CLNY -3%. GPN -3%. GPL -3%.
    | Comment!
  • Feb. 5, 2010, 9:10 AM
    Premarket gainers: ARG +43%. PWER +19%. OPTR +18%. TSTC +8%. BZH +6%. TSN +5%. AVII +5%. WFR +4%. SOLF +4%. ABK +4%. CPST +4%.
    Losers: PFWD -21%. LEAP -5%. ING -4%. AIXG -4%. UN -4%. AXA -4%. LYG -4%.
    | Comment!
Visit Seeking Alpha's
Company Description
Currently, there's no company description for OPTR.
Sector: Healthcare
Industry: Biotechnology
Country: United States